CELESTIMO Phase III Win Opens Earlier FL Line, But Comparator Silence Clouds Market Access Case

Roche's Lunsumio Regimen Improves PFS in Follicular Lymphoma

Roche announced that its phase III CELESTIMO study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Lunsumio (mosunetuzumab) in combination with lenalidomide. The study involved people with relapsed or refractory follicular lymphoma (FL) who had received at least one prior line of treatment. The safety profile of the Lunsumio and lenalidomide combination was consistent with known profiles, with no new safety signals identified. These data will be submitted to health authorities and presented at an upcoming medical meeting, reinforcing the potential for an effective new outpatient option earlier in the treatment journey for FL patients.

• The CELESTIMO study, a confirmatory Phase III trial (NCT04712097), successfully met its primary endpoint at an interim analysis, showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the Lunsumio and lenalidomide combination. This outcome is crucial for patients with relapsed or refractory follicular lymphoma who have undergone at least one prior line of treatment.
• The positive results from CELESTIMO are intended to convert the accelerated approval of Lunsumio monotherapy for third-line or later FL to full approval, and to secure an expanded indication for second-line or later FL. This positions the Lunsumio-based regimen as a potential earlier-line, outpatient treatment option, offering a simple dosing schedule and a tolerable safety profile consistent with individual drug profiles.
• Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody, designed to redirect a patient's T cells to eliminate malignant B cells. This study reinforces its role within Roche's extensive bispecific antibody program, which includes ongoing trials in various B-cell malignancies like diffuse large B-cell lymphoma (DLBCL) and first-line FL, aiming to redefine care across these diseases.

Why New Options for Relapsed FL Are Urgently Needed

Despite meaningful advances in first-line chemoimmunotherapy, follicular lymphoma (FL) remains incurable in advanced stages, and a clinically significant subset of patients faces poor outcomes that current treatment paradigms have not resolved. The challenges span early disease progression, histological transformation, long-term toxicity, and the diminishing efficacy of successive treatment lines.

• POD24 identifies a high-risk population with markedly inferior survival. Approximately 19–20% of patients with FL experience disease progression within 24 months of front-line chemoimmunotherapy. In a pooled analysis of 13 randomized clinical trials (n = 5,225), POD24 was associated with poor subsequent overall survival, with hazard ratios of 4.85 (time-dependent Cox model) and 3.06 (24-month landmark analysis). In the National LymphoCare Study, 5-year overall survival was 50% in the early-POD group versus 90% in the reference group (FLIPI-adjusted hazard ratio, 6.44; 95% CI, 4.33–9.58). Clinical predictors of POD24 include male sex (OR, 1.30), performance status ≥2 (OR, 1.63), β2-microglobulin ≥3 mg/L (OR, 1.43), and high-risk FLIPI score of 3–5 (OR, 3.14).

• Histological transformation carries a poor prognosis and lacks validated predictive tools. FL can undergo histological transformation (HT) to a more aggressive disease, most commonly diffuse large B-cell lymphoma (DLBCL). In the GALLIUM study, patients with biopsy-confirmed HT at first progression had a 2-year post-progression survival rate of 55.9%, compared with 83.1% for those with relapsed FL, and HT relapse occurred earlier (median 0.8 vs. 2.3 years from randomization). Risk factors for HT include male sex (sHR, 2.21), elevated baseline serum LDH (sHR, 3.97), and elevated baseline serum β2-microglobulin (sHR, 1.96). In the JCOG0203 10-year follow-up, the cumulative incidence of histological transformation reached 9.3% at 10 years. A validated prognostic model for HT risk does not yet exist.

• Long-term toxicity of chemoimmunotherapy poses a sustained clinical burden. Extended treatment regimens carry meaningful toxicity profiles. In SWOG S0801, grade 3 or worse adverse events included neutropenia (57%), leucopenia (40%), thrombocytopenia (20%), and febrile neutropenia (17%); secondary malignancies occurred in seven patients, including two acute myelogenous leukaemias. The JCOG0203 trial reported a 10-year cumulative incidence of secondary malignancies of 8.1%, with haematological secondary malignancies at 2.9%. Prolonged maintenance rituximab also proved infeasible for many patients, with most discontinuations occurring during the maintenance phase in SWOG S0801.

• Efficacy of CAR-T therapy in real-world settings falls short of clinical trial benchmarks. In a multicenter retrospective cohort of 136 patients with relapsed/refractory FL receiving commercial CAR-T (axicabtagene ciloleucel or tisagenlecleucel), progression-free survival was inferior to that reported in clinical trials. After inverse probability of treatment weighting, efficacy outcomes were largely similar between the two products, yet axicabtagene ciloleucel remained associated with significantly higher toxicity, including ICANS in 42% of patients versus 17% with tisagenlecleucel (p = 0.008). Real-world populations are often not representative of clinical trial cohorts, limiting the generalizability of pivotal trial results.

• Outcomes in relapsed/refractory FL worsen with each successive treatment line. CR rates decline and disease progression accelerates with each treatment line, with particularly poor outcomes in patients with high-risk features. In the ELM-2 study of odronextamab in heavily pretreated R/R FL, cytokine release syndrome was the most common treatment-emergent adverse event (56.4% in patients achieving CR), and treatment-emergent adverse events led to discontinuation in 16.0% of patients with CR, underscoring the ongoing challenge of balancing efficacy and tolerability in this setting.

Unpacking the CELESTIMO Study Design and PFS Breakthrough

Several key trials have evaluated novel and established regimens across the follicular lymphoma (FL) treatment landscape, spanning first-line, relapsed/refractory, and combination immunotherapy settings. The studies below represent a cross-section of phase 1/2 and phase 3 designs, each with distinct patient populations, intervention strategies, and endpoint structures.

Lunsumio's Combination Data: A New Frontier in Earlier FL Treatment

The positive Phase III CELESTIMO results for Lunsumio (mosunetuzumab) in combination with lenalidomide mark a significant advancement for patients with relapsed or refractory follicular lymphoma (FL) who have received at least one prior line of treatment. This data positions Lunsumio to move into an earlier treatment setting, expanding its utility beyond its current approval as monotherapy for patients who have undergone two or more prior therapies. The demonstration of a statistically significant and clinically meaningful improvement in progression-free survival (PFS), coupled with a consistent safety profile, underscores the potential for this combination to become a new standard of care.

This development is particularly impactful given the increasing focus on chemotherapy-free regimens and outpatient administration in oncology. Mosunetuzumab, as a T-cell engaging bispecific antibody, already offers an off-the-shelf, fixed-duration treatment option suitable for outpatient use. Its combination with lenalidomide, an established immunomodulatory drug, leverages known mechanisms to enhance efficacy while maintaining a manageable safety profile. This offers a compelling value proposition for patients seeking effective, less burdensome treatment options.

However, the evolving landscape for R/R FL presents a dynamic competitive environment. Other bispecific antibodies, such as epcoritamab in combination with rituximab and lenalidomide, have also demonstrated superior efficacy in the second-line setting, positioning themselves as new standards. Furthermore, CAR T-cell therapies like axicabtagene ciloleucel and lisocabtagene maraleucel, while typically reserved for later lines due to their complexity and higher rates of certain adverse events, have shown superior efficacy outcomes compared to mosunetuzumab monotherapy in 3L+ FL. The cost-effectiveness of the mosunetuzumab-lenalidomide combination will also be a critical factor, especially considering prior analyses indicated mosunetuzumab monotherapy was not cost-effective against R-Len. Roche will need to clearly articulate the unique benefit-risk and economic value of this combination to secure market share in this increasingly crowded and innovative therapeutic area. The upcoming data presentation will be crucial for detailing the full clinical profile and informing its strategic trajectory.